TMBR stock soars on FDA Breakthrough Designation for skin disease therapy (NYSE:TMBR)
seekingalpha.com
finance
2022-05-31 12:21:16

Grandbrothers/iStock Editorial via Getty Images The shares of Timber Pharmaceuticals (NYSE:TMBR) added ~56% in the pre-market Tuesday after the dermatology-focused biotech announced that the FDA awarded the Breakthrough Therapy designation for its lead asset TMB-001 in congenital ichthyosis (CI). TMB-001 is a topical formulation of isotretinoin designed to treat moderate to severe forms of CI, a group of rare genetic skin disorders. The company is targeting a pivotal Phase 3 study for the candidate after a mid-stage trial indicated its efficacy with a favorable safety profile in CI.
